Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A071601||Alliance||Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0534||RTOG||A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1302||ECOG||Phase III Randomized; Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa; Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-39||NSABP||A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0; I; or II Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5163||ECOG-ACRIN||INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA4151||ECOG-ACRIN||A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0252||GOG||A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian; Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab (NSC #704865; IND #113912)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GU001||NRG||Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0334||SWOG||Myeloma Specimen Repository Protocol Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|E4201||ECOG||A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy Versus Gemcitabine Alone in Patients with Localized; Unresectable Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Completed|